Clinical Trial
Preliminary clinical trial of immunotherapy for malignant glioma
Affiliations
- PMID: 3316510
Item in Clipboard
Clinical Trial
Preliminary clinical trial of immunotherapy for malignant glioma
J Biol Response Mod.
1987 Oct.
Abstract
An immunotherapy protocol based on intracranial implantation of stimulated, autologous lymphocytes into the tumor bed following surgical debulking of malignant glioma is described. Phase I clinical trials in human patients are now in progress. Preliminary data representing the first 39 patients treated are presented briefly.
Similar articles
-
Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.Cancer Res. 1986 Apr;46(4 Pt 2):2101-4. Cancer Res. 1986. PMID: 3512079 Clinical Trial.
-
Salvage immunotherapy of malignant glioma.Arch Surg. 1987 Dec;122(12):1483-6. doi: 10.1001/archsurg.1987.01400240131025. Arch Surg. 1987. PMID: 3500693
-
[Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].No To Shinkei. 1986 Jun;38(6):593-8. No To Shinkei. 1986. PMID: 3488068 Japanese.
-
Cell- and peptide-based immunotherapeutic approaches for glioma.Trends Mol Med. 2008 May;14(5):228-35. doi: 10.1016/j.molmed.2008.03.003. Epub 2008 Apr 9. Trends Mol Med. 2008. PMID: 18403264 Review.
-
Adoptive immunotherapy of CNS malignancies.Cancer Chemother Biol Response Modif. 2001;19:327-38. Cancer Chemother Biol Response Modif. 2001. PMID: 11686021 Review.
Cited by
-
Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.Proc Natl Acad Sci U S A. 1990 Dec;87(24):9577-81. doi: 10.1073/pnas.87.24.9577. Proc Natl Acad Sci U S A. 1990. PMID: 2263613 Free PMC article.
-
Effects of route and formulation on clinical pharmacokinetics of interleukin-2.Clin Pharmacokinet. 1994 Jul;27(1):19-31. doi: 10.2165/00003088-199427010-00003. Clin Pharmacokinet. 1994. PMID: 7955769 Review.
-
Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.J Neurooncol. 1990 Apr;8(2):173-88. doi: 10.1007/BF00177842. J Neurooncol. 1990. PMID: 2193121 Review.
-
Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.J Neurooncol. 1991 Oct;11(2):85-147. doi: 10.1007/BF02390173. J Neurooncol. 1991. PMID: 1744686 Review. No abstract available.
-
Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.Am J Pathol. 1996 Apr;148(4):1139-52. Am J Pathol. 1996. PMID: 8644856 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical